- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Conditions for Administering Bispecific Therapy
Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.
EP: 1.Conditions for Administering Bispecific Therapy
EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics
EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration
EP: 4.Pain Points In Bispecific Operationalization
EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy
EP: 6.Optimizing Bispecific Use Through EMR Utilization
EP: 7.Best Practices For Uptake and Use of Bispecific Therapy
EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy
EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions
EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies
EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care
EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies
EP: 13.Managed Care Considerations Within Bispecific Landscape
EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies
EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy
EP: 16.Bispecific Therapies: Current and Future Considerations
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
The video discusses considerations for operationalizing bispecific monoclonal antibodies in cancer care. It highlights the importance of having protocols in place for patient monitoring, transition of care, risk evaluation and mitigation strategies programs, management of adverse events like cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, and long-term toxicity monitoring. Key factors include setting patient eligibility criteria, caregiver reliability for adherence, transportation to handle severe adverse effects, and financial considerations for insurance authorizations. As these are continuous therapies, extensive plans must be made to support patients across the entirety of their treatment journey.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
